BIO comments submitted in response to a USDA-Animal and Plant Health Inspection Service request for public comment on APHIS' new strategic plan to guide the agency's work over the next five years.
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
BIO comments submitted in response to a USDA-Animal and Plant Health Inspection Service request for public comment on APHIS' new strategic plan to guide the agency's work over the next five years.